Investigating the Safety and Efficacy of the Treatment With the Non-compliant Jade Balloon in TASC C and D Athero-occlusive Infra-inguinal Disease in Patients With Chronic Limb Threatening Limb Ischemia From SingaporE

Inclusion Criteria: 1. Age of subject is \> 40 years old. Patient covered by MediShield insurance as provided by Singapore government. 2. Patient has critical limb ischemia, presenting a score from 4 to 6 following the Rutherford classification 3. Patients must agree to return for all required post-index procedure follow-up visits. 4. Patient understands the nature of the procedure and provides written informed consent, prior to enrolment in the study 5. Patient has a projected life expectancy of at least 12 months and has not suffered a myocardial infarction within past 30 days Angiographic Inclusion Criteria: 1. De novo and post-PTA re-stenotic lesions located in the superficial femoral, popliteal and tibial arteries suitable for endovascular therapy 2. The target lesion is located within the native SFA/popliteal/tibial artery 3. The length of the target lesion(s) is \> 100mm and considered as TASC C or D lesion according to the TASC II classification. 4. The target lesion has angiographic evidence of stenosis \> 50% or occlusion, which has been passed with standard guidewire manipulation and no other adjunctive devices have been used to prepare the lesion (example scoring balloon, rotablator, atherectomy device) 5. Target vessel diameter visually estimated is \>1.5mm and \< 6.5mm below the groin 6. Prior to enrolment, the guidewire has crossed the target lesion 7. Lesions in the treated segment may be continuous or may have gaps present between stenoses and occlusions 8. Inflow iliac, common femoral artery lesions can be treated during the same procedure using standard angioplasty and/or approved device/open surgery. These inflow lesions must be treated first prior to consideration of treatment of the distal lying lesions. The patient can be enrolled if the inflow lesions are treated with good embolization) 9. There is angiographic evidence of at least one- vessel-runoff through the ankle and into the foot, irrespective of whether or not outflow was re- established by means of previous endovascular intervention Exclusion Criteria: 1. Patient is permanently wheel-chair bound or bedridden 2. Presence of a stent in the target lesion(s) that was placed during a previous procedure 3. The intervention is being performed in preparation for a planned amputation. 4. Untreated flow-limiting inflow lesions 5. Any previous surgery in the target vessel (including prior ipsilateral crural bypass) 6. Previous bypass surgery in the same limb 7. Patients with a history of Myocardial Infarction (MI), thrombolysis or angina within 30 days prior-index procedure. 8. Patients with a history of major disabling stroke within 3 months prior index procedure. 9. Patients with any type of previous or planned surgical or interventional procedure within 15 days prior- and/or within 30 days post-index procedure. 10. Untreatable lesion located at the distal outflow arteries 11. Patients with uncorrected bleeding disorders 12. Aneurysm located at the level of the SFA/popliteal artery 13. Non-atherosclerotic disease resulting in occlusion (e.g. embolism, Buerger's disease, vasculitis) 14. Any condition which prevents patient from complying with the study protocol or if patient has a life expectancy of \<1yr. 15. Major distal amputation (above the transmetatarsal) in the study limb or non-study limb 16. Patients with a presence or history of severe renal failure (Glomerular Filtration Rate (GFR) ≤ 30 ml/min) and is not dialysis dependent. 17. Neurotrophic ulcer or heel pressure ulcer or ulcer potentially involving calcaneus (index limb) 18. Episode of acute limb ischaemia within the previous 1 month 19. Use of thrombectomy, cutting balloon, lithotripsy, atherectomy or laser devices during procedure 20. Any patient considered to be hemodynamically unstable at onset of procedure 21. Patients with a known hypersensitivity or contraindication to aspirin, heparin, clopidogrel, or other anticoagulant/anti-platelet therapies or sensitivity to contrast media that cannot be adequately premedicated. 22. The patient is currently breast-feeding, pregnant or intends to become pregnant. 23. Subject receiving immunosuppression therapy, or has known serious immunosuppressive disease (e.g., human immunodeficiency virus), or has severe autoimmune disease that requires chronic immunosuppressive therapy (e.g., systemic lupus erythematosus, etc.) The patient should also not receive inhibitors of CYP3A (such as Itraconazole, and Erythromycin), or inducers of CYP3A (such as Rifampin) within 90 days following the procedure. 24. Patient is participating in another research study of a device, medication, biologic or other agent within 30 days which could in the opinion of the investigator affect the results of this study 25. Patients with any contraindications as mentioned in the Instructions for Use (IFU) of the Investigational Device.